Ones To Watch News
Refine search
Biotechnology
The recent news flow at Dewpoint Therapeutics—the firm making condensate biology a clinical reality—has been striking in its volume and significance. 10 March 2026
Biotechnology
Sino-American oncology specialist BeOne Medicines today announced that the Health Service Executive (HSE) in the Republic of Ireland has approved reimbursement of tislelizumab, (trade name Tevimbra) in combination with platinum-based chemotherapy, for the first-line treatment of eligible adult patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (OSCC) whose tumors express PD-L1. 10 March 2026
Biotechnology
French biotech OSE Immunotherapeutics announced the transition of Marc Le Bozec from interim to permanent chief executive (CEO), effective immediately. Mr Le Bozec had served as interim CEO since October 2, 2025. 10 March 2026
Biotechnology
US biotech Dianthus Therapeutics saw its shares leap 21.5% to $79.23 yesterday, after it announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. 10 March 2026
Biotechnology
French biotech start-up kyron.bio, which is pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, a France-based group governed by a Foundation. 9 March 2026
Biotechnology
Dutch biotech uniQure closed Friday’s trading 34% higher - and was up by a similar amount again in pre-market Monday - as the chaos and confusion intensified around AMT-130, its investigational gene therapy for Huntington’s disease (HD). 9 March 2026
Biotechnology
The European Commission (EC) on Friday approved Incyte’s Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). 9 March 2026
Pharmaceutical
Hangzhou Sciwind Biosciences, a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, today announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. 6 March 2026
Biotechnology
Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration. 6 March 2026
Biotechnology
Cambridge, USA-based precision allosteric therapeutics biotech Atavistik Bio has announced the closing of a $40 million extension to its Series B financing from new investor RA Capital Management, bringing the total round proceeds to $160 million. 6 March 2026
Pharmaceutical
Canada based clinical-stage pharma Helus Pharma today announced top-line results from a Phase II signal detection study evaluating HLP004 as a potential treatment for adults with moderate-to-severe generalized anxiety disorder (GAD) who remained symptomatic despite ongoing SoC antidepressant therapy, including selective serotonin reuptake inhibitors and related agents. 5 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. 5 March 2026
Pharmaceutical
French pharma Sanofi has agreed to license the experimental drug rovadicitinib from China’s Sino Biopharmaceutical, paying $135 million upfront for exclusive development and commercialization rights outside China. 5 March 2026
Biotechnology
Chinese cell therapy developer Lemang Biotech has raised nearly 200 million yuan ($28 million) in fresh financing to advance clinical development of its metabolism-enhanced CAR-T therapies and scale up manufacturing. 5 March 2026
Biotechnology
Shares of Hansa Biopharma rose nearly 7% to 32.98 kronor, after the Swedish company announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 5 March 2026
Biotechnology
US biotech Prolium Bioscience has announced its launch with a $50 million Series A financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. 4 March 2026
Biotechnology
US biotechnology company Candid Therapeutics will go public through a reverse merger with US rare disease drugmaker Rallybio, creating a Nasdaq-listed company focused on T-cell engager therapies for autoimmune diseases. 4 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Biotechnology
The recent news flow at Dewpoint Therapeutics—the firm making condensate biology a clinical reality—has been striking in its volume and significance. 10 March 2026
Biotechnology
Sino-American oncology specialist BeOne Medicines today announced that the Health Service Executive (HSE) in the Republic of Ireland has approved reimbursement of tislelizumab, (trade name Tevimbra) in combination with platinum-based chemotherapy, for the first-line treatment of eligible adult patients with unresectable, locally advanced recurrent or metastatic esophageal squamous cell carcinoma (OSCC) whose tumors express PD-L1. 10 March 2026
Biotechnology
French biotech OSE Immunotherapeutics announced the transition of Marc Le Bozec from interim to permanent chief executive (CEO), effective immediately. Mr Le Bozec had served as interim CEO since October 2, 2025. 10 March 2026
Biotechnology
US biotech Dianthus Therapeutics saw its shares leap 21.5% to $79.23 yesterday, after it announced that it has commenced an underwritten public offering of $400 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. 10 March 2026
Biotechnology
French biotech start-up kyron.bio, which is pioneering precision glycoengineering for antibody therapeutic development, today announced a strategic partnership with Servier, a France-based group governed by a Foundation. 9 March 2026
Biotechnology
Dutch biotech uniQure closed Friday’s trading 34% higher - and was up by a similar amount again in pre-market Monday - as the chaos and confusion intensified around AMT-130, its investigational gene therapy for Huntington’s disease (HD). 9 March 2026
Biotechnology
The European Commission (EC) on Friday approved Incyte’s Zynyz (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). 9 March 2026
Pharmaceutical
Hangzhou Sciwind Biosciences, a biopharmaceutical company focused on the discovery and development of innovative therapies for metabolic diseases, today announced that China's National Medical Products Administration (NMPA) has approved ecnoglutide injection for chronic weight management in Chinese adults with overweight or obesity. 6 March 2026
Biotechnology
Shares of US clinical-stage biotech Tenaya Therapeutics closed up more than 40% at $0.82 yesterday following its announcement of a potentially lucrative collaboration. 6 March 2026
Biotechnology
Cambridge, USA-based precision allosteric therapeutics biotech Atavistik Bio has announced the closing of a $40 million extension to its Series B financing from new investor RA Capital Management, bringing the total round proceeds to $160 million. 6 March 2026
Pharmaceutical
Canada based clinical-stage pharma Helus Pharma today announced top-line results from a Phase II signal detection study evaluating HLP004 as a potential treatment for adults with moderate-to-severe generalized anxiety disorder (GAD) who remained symptomatic despite ongoing SoC antidepressant therapy, including selective serotonin reuptake inhibitors and related agents. 5 March 2026
Pharmaceutical
USA-based Biologos, an ISO 13485–certified and GMP-compliant manufacturer of custom sterile-filtered liquid solutions, today announced the appointment of Hetal Patel as chief executive. 5 March 2026
Pharmaceutical
Medicus Pharma has announced top-line results from its Phase II study of doxorubicin microneedle array (D-MNA) to non-invasively treat basal cell carcinoma (BCC) of the skin. 5 March 2026
Pharmaceutical
French pharma Sanofi has agreed to license the experimental drug rovadicitinib from China’s Sino Biopharmaceutical, paying $135 million upfront for exclusive development and commercialization rights outside China. 5 March 2026
Biotechnology
Chinese cell therapy developer Lemang Biotech has raised nearly 200 million yuan ($28 million) in fresh financing to advance clinical development of its metabolism-enhanced CAR-T therapies and scale up manufacturing. 5 March 2026
Biotechnology
Shares of Hansa Biopharma rose nearly 7% to 32.98 kronor, after the Swedish company announced that the Food and Drug Administration (FDA) has notified the company that the previously accepted Biologics License Application (BLA) for imlifidase has been assigned a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2026. 5 March 2026
Biotechnology
US biotech Prolium Bioscience has announced its launch with a $50 million Series A financing to develop PRO-203, a potential best-in-class CD20xCD3 T-cell engager, for severe autoimmune disease. 4 March 2026
Biotechnology
US biotechnology company Candid Therapeutics will go public through a reverse merger with US rare disease drugmaker Rallybio, creating a Nasdaq-listed company focused on T-cell engager therapies for autoimmune diseases. 4 March 2026
Pharmaceutical
US neuro-focused company NeuroOne has appointed David Wambeke as chief business officer, tasking him with leading the firm’s drug delivery program as it seeks partnerships around its neurological treatment platform. 4 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze